Edition:
India

Avadel Pharmaceuticals PLC (AVDL.OQ)

AVDL.OQ on NASDAQ Stock Exchange Global Market

7.92USD
1:05am IST
Change (% chg)

$0.26 (+3.39%)
Prev Close
$7.66
Open
$7.74
Day's High
$7.92
Day's Low
$7.59
Volume
93,144
Avg. Vol
227,492
52-wk High
$13.48
52-wk Low
$1.86

Select another date:

Wed, Jul 1 2020

BRIEF-Avadel Announces Sale Of Hospital Sterile Injectable Drug Portfolio For $42 Million

* AVADEL ANNOUNCES SALE OF HOSPITAL STERILE INJECTABLE DRUG PORTFOLIO FOR $42.0 MILLION

BRIEF-Avadel Files For Offering Of 9.2 Mln Shares Represented By ADS By Selling Stockholders

* AVADEL PHARMACEUTICALS PLC FILES FOR OFFERING OF 9.2 MILLION SHARES REPRESENTED BY ADS BY SELLING STOCKHOLDERS - SEC FILING Source text (https://bit.ly/2Bx1NJx) Further company coverage:

BRIEF-Avadel Pharmaceuticals Reports First Quarter 2020 Financial Results

* AVADEL PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Avadel - Files Prospectus Related To Proposed Resale/Other Disposition By Selling Shareholders Of 9.2 Mln Shares Represented By ADS

* AVADEL PHARMACEUTICALS - FILES PROSPECTUS RELATED TO PROPOSED RESALE/OTHER DISPOSITION BY SELLING SHAREHOLDERS OF 9.2 MILLION OF ORDINARY SHARES REPRESENTED BY ADS Source text for Eikon: https://bit.ly/3d8hkNm Further company coverage:

BRIEF-Avadel Pharmaceuticals Announces Proposed Public Offering

* AVADEL PHARMACEUTICALS ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING

BRIEF-Avadel Pharma Announces Positive Topline Results From Pivotal Phase 3 REST-ON Trial

* AVADEL PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE RESULTS FROM ITS PIVOTAL PHASE 3 REST-ON TRIAL OF ONCE-NIGHTLY FT218 FOR THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS AND CATAPLEXY IN PATIENTS WITH NARCOLEPSY

BRIEF-Avadel Pharmaceuticals Completes The Rest-On Phase 3 Pivotal Trial Of FT218 For Excessive Daytime Sleepiness And Cataplexy In Patients With Narcolepsy

* AVADEL PHARMACEUTICALS COMPLETES THE REST-ON PHASE 3 PIVOTAL TRIAL OF FT218 FOR EXCESSIVE DAYTIME SLEEPINESS AND CATAPLEXY IN PATIENTS WITH NARCOLEPSY

BRIEF-Avadel Pharmaceuticals Reports Q4 And Full Year 2019 Financial Results

* AVADEL PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-Vivo Opportunity Reports 6.2% Passive Stake In Avadel Pharma As Of Feb 25

* VIVO OPPORTUNITY LLC REPORTS 6.2% PASSIVE STAKE IN AVADEL PHARMACEUTICALS PLC AS OF FEBRUARY 25, 2020 - SEC FILING Source text: (http://bit.ly/2VK1rHn)

Select another date: